Jazz Pharmaceuticals PLC shares fell 1.6% on Friday following an announcement that Zepzelca did not meet the primary endpoint in a late-stage lung cancer study.
The Phase 3 LAGOON trial, run by PharmaMar, evaluated Zepzelca as a single agent and in combination with irinotecan versus investigators' choice of topotecan or irinotecan in patients with relapsed metastatic small cell lung cancer. The study did not demonstrate a statistically significant improvement in overall survival for either Zepzelca monotherapy or the combination arm compared with the control arm.
Investigators reported no new safety signals associated with Zepzelca. Overall safety observations in LAGOON were described as consistent with the known safety profiles of the agents used in the trial.
LAGOON enrolled a broader patient population than the earlier Phase 2 pivotal study that supported the drug's accelerated approval for second-line use, explicitly including patients with a history of central nervous system involvement. Median overall survival across the full trial population was reported as 8.7 months for Zepzelca monotherapy, 10.9 months for Zepzelca plus irinotecan, and 10.7 months in the control arm.
Jazz Pharmaceuticals stated the LAGOON outcomes do not affect the pathway to full U.S. approval in 2025 for Zepzelca based on results from the Phase 3 IMforte trial. IMforte evaluated Zepzelca in combination with the PD-L1 inhibitor atezolizumab as first-line maintenance treatment for patients with extensive-stage small cell lung cancer. In IMforte, the combination reportedly reduced the risk of disease progression or death by 46% and reduced the risk of death by 27% compared with atezolizumab alone.
The company has shared the LAGOON data with the U.S. Food and Drug Administration and plans to discuss next steps related to post-marketing requirements tied to Zepzelca's second-line indication. Jazz also said the LAGOON findings do not change its guidance for 2026.
Context for investors
- Market reaction - The reported 1.6% share decline reflects investor response to the missed primary endpoint.
- Regulatory follow-up - Jazz is engaging with the FDA to determine implications for post-marketing commitments related to the second-line approval.
- Ongoing approval pathway - Jazz maintains that the IMforte-based full approval timeline for 2025 remains intact.
The LAGOON results underscore differences in outcomes between trials that enroll broader populations and earlier pivotal studies with narrower eligibility criteria. Jazz's statement highlighted that safety remained consistent with expectations and emphasized the separate dataset from IMforte that underpins the company's full approval plans.